Company Overview and News
SINGAPORE: Joanne Kua, Group Chief Executive Officer and Executive Director of Malaysia-based KSK Group, is listed in the Forbes Asia's inaugural Emergent 25 List which honours businesswomen making their mark in regional enterprises. Kua, 33, who is also the managing director of KSK Land Sdn Bhd, joined her father's insurance and finance business seven years ago. Since then, she has transformed KSK Group into a diversified conglomerate by adding property development and technology investments to its portfolio and the group's total assets was now worth around US$410 million (US$1 = RM3.
Director share buying surged for the second straight week, while selling rose for the fourth straight week, based on filings on the exchange during the holiday-shortened week of March 26 to 29.
LAST year was dotted by the return of higher commodity prices and better economic growth. The world’s economies on average are back in business as growth rates and trade have started to improve once again after some period of uncertainty caused by a cooling China economy and also the slump in global crude oil prices.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
KUOK is often mistaken for a “Tan Sri” or “Tun”. But the 94-year-old tycoon, who was born in Johor but is based in Hong Kong, is neither.
The buying remained high while the selling among directors fell based on filings on the Hong Kong Stock Exchange for the week ended October 7. A total of 26 companies recorded 112 purchases worth HK$82 million versus 12 firms with 72 disposals worth HK$152 million. The number of companies and trades on the buying side were consistent with the previous week’s 26 firms and 104 acquisitions. The buy value, however, was down from the previous week’s purchases worth HK$103 million.
This replaces announcement number 3817K released at 07.00 BST on 21 September 2016. Under Financial Highlights, the third bullet point has been amended to read "IFRS NAV was US$106.6 million or US$1.40 (105 pence*) per share, a 30% drop over the reporting period", and the third bullet point now reads "Share price discount to Adjusted NAV per share widened from 17% to 53%, based on the Fund's share price of 105 pence at the period end".
Macau Property Opportunities Fund Limited announces its results for the year ended 30 June 2016. The Company, which is managed by Sniper Capital Limited, develops and invests in real estate opportunities in Macau.
In just a few years, Evergrande Real Estate Group (OTC:EGRNF), (OTCPK:EGRNY), (3333.HK) has grown from a mid-sized, regional property company into one of China's largest developers. Its extraordinary growth has been mainly debt-financed. Evergrande is highly leveraged with large borrowings and other liabilities balanced on a small sliver of equity: total debt is now over four times shareholders' equity.
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...